0
Consolidated first semester sales of Ceva Group reached €366.5m at the end of June representing growth of 18.3% versus last year. At constant perimeter (without Sogeval acquisition end of 2013) and exchange rates, growth was 10.8%. Unfavourable exchange rate movements impacted sales €22m.
Sales grew in all zones, with particularly strong performance from the companion animal sector (+12%), where Vectra, Ceva’s leading topical parasiticide for companion animals benefited from strong sales in the US and a successful launch across the European Union.
Ceva began its 4th and latest LMBO on July, 1st 2014, following a highly successful reshaping of its capital structure to include a diverse range of new shareholders who will help Ceva to achieve its ambition to enter the top 5 of the global animal health companies by 2020.
Marc Prikazsky, Ceva’s Chairman and CEO commented, “To finish the last 6 months of our previous LMBO on such a high note is extremely pleasing. Our new shareholders have placed a lot of confidence in the future of our business, not least the management team who re-invested very significantly to retain majority control. These results demonstrate that we have the right platform in place to deliver future sustained growth.”
July 23, 2014 - Ceva
